InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,214.08
(
0.51%
)
US TECH 100
17,660.00
(
0.33%
)
Dow Jones
39,387.76
(
0.85%
)
Brent Oil
84.05
(
0.11%
)
Bitcoin
62,835.29
(
-0.34%
)
Post# of 1367
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

midastouch017

Send PM Follow Ignore
Followers 145
Posts 27566
Boards Moderated 3
Alias Born 02/07/2004

midastouch017

Re: None

Thursday, 09/29/2016 9:14:22 AM

Thursday, September 29, 2016 9:14:22 AM

Post# of 1367
Allergan's $1.7 Billion Acquisition of Tobira for NASH Drug Sets 1750% Potential Premium on Can-Fite Stock

#msg-125465359

Can-Fite also has Piclidenoson, headed into two Phase III trials addressing multi-billion dollar autoimmune disease markets, all for a market cap under $30 million. Can-Fite makes for a very attractive acquisition target.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up